Delivery Rate Affects Uptake of a Fluorescent Glucose Analog in Murine Metastatic Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 9

PMID 24204635

Citations 18

Authors

Narasimhan Rajaram

Amy E Frees

Andrew N Fontanella

Jim Zhong

Katherine Hansen

Mark W Dewhirst

Nirmala Ramanujam

Affiliations

Soon will be listed here.

Abstract

We demonstrate an optical strategy using intravital microscopy of dorsal skin flap window chamber models to image glucose uptake and vascular oxygenation in vivo. Glucose uptake was imaged using a fluorescent glucose analog, 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2-deoxyglucose (2-NBDG). SO2 was imaged using the differential absorption properties of oxygenated [HbO2] and deoxygenated hemoglobin [dHb]. This study was carried out on two sibling murine mammary adenocarcinoma lines, 4T1 and 4T07. 2-NBDG uptake in the 4T1 tumors was lowest when rates of delivery and clearance were lowest, indicating perfusion-limited uptake in poorly oxygenated tumor regions. For increasing rates of delivery that were still lower than the glucose consumption rate (as measured in vitro), both 2-NBDG uptake and the clearance rate from the tumor increased. When the rate of delivery of 2-NBDG exceeded the glucose consumption rate, 2-NBDG uptake decreased with any further increase in rate of delivery, but the clearance rate continued to increase. This inflection point was not observed in the 4T07 tumors due to an absence of low delivery rates close to the glucose consumption rate. In the 4T07 tumors, 2-NBDG uptake increased with increasing rates of delivery at low rates of clearance. Our results demonstrate that 2-NBDG uptake in tumors is influenced by the rates of delivery and clearance of the tracer. The rates of delivery and clearance are, in turn, dependent on vascular oxygenation of the tumors. Knowledge of the kinetics of tracer uptake as well as vascular oxygenation is essential to make an informed assessment of glucose demand of a tumor.

Citing Articles

Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence.

Sunassee E, Deutsch R, DAgostino V, Castellano-Escuder P, Siebeneck E, Ilkayeva O Sci Adv. 2024; 10(14):eadj7540.

PMID: 38579004 PMC: 10997195. DOI: 10.1126/sciadv.adj7540.

In vivo metabolic imaging identifies lipid vulnerability in a preclinical model of Her2+/Neu breast cancer residual disease and recurrence.

Madonna M, Duer J, McKinney B, Sunassee E, Crouch B, Ilkayeva O NPJ Breast Cancer. 2022; 8(1):111.

PMID: 36163365 PMC: 9512922. DOI: 10.1038/s41523-022-00481-3.

Augmentation of RBP4/STRA6 signaling leads to insulin resistance and inflammation and the plausible therapeutic role of vildagliptin and metformin.

Gokulakrishnan K, Pandey G, Sathishkumar C, Sundararajan S, Durairaj P, Manickam N Mol Biol Rep. 2021; 48(5):4093-4106.

PMID: 34041677 DOI: 10.1007/s11033-021-06420-y.

In Vivo Optical Metabolic Imaging of Long-Chain Fatty Acid Uptake in Orthotopic Models of Triple-Negative Breast Cancer.

Madonna M, Duer J, Lee J, Williams J, Avsaroglu B, Zhu C Cancers (Basel). 2021; 13(1).

PMID: 33466329 PMC: 7794847. DOI: 10.3390/cancers13010148.

Spatially resolved measurement of dynamic glucose uptake in live ex vivo tissues.

Dunn A, Catterton M, Dixon D, Pompano R Anal Chim Acta. 2020; 1141:47-56.

PMID: 33248661 PMC: 7701360. DOI: 10.1016/j.aca.2020.10.027.

References

Heppner G, Miller F, Shekhar P . Nontransgenic models of breast cancer. Breast Cancer Res. 2001; 2(5):331-4. PMC: 138654. DOI: 10.1186/bcr77. View

Millon S, Ostrander J, Brown J, Raheja A, Seewaldt V, Ramanujam N . Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. Breast Cancer Res Treat. 2010; 126(1):55-62. DOI: 10.1007/s10549-010-0884-1. View

Sorg B, Moeller B, Donovan O, Cao Y, Dewhirst M . Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J Biomed Opt. 2005; 10(4):44004. DOI: 10.1117/1.2003369. View

Moeller B, Dreher M, Rabbani Z, Schroeder T, Cao Y, Li C . Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005; 8(2):99-110. DOI: 10.1016/j.ccr.2005.06.016. View

King L, Opie L . Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. Cardiovasc Res. 1998; 39(2):381-92. DOI: 10.1016/s0008-6363(98)00100-x. View

ONeil R, Wu L, Mullani N . Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol. 2005; 7(6):388-92. DOI: 10.1007/s11307-005-0011-6. View

Tao K, Fang M, Alroy J, Sahagian G . Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008; 8:228. PMC: 2529338. DOI: 10.1186/1471-2407-8-228. View

Semple S, Gilbert F, Redpath T, Staff R, Ahearn T, Welch A . The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004; 14(11):2038-45. DOI: 10.1007/s00330-004-2454-6. View

Yoshioka K, Oh K, Saito M, Nemoto Y, Matsuoka H . Evaluation of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose, a new fluorescent derivative of glucose, for viability assessment of yeast Candida albicans. Appl Microbiol Biotechnol. 1996; 46(4):400-4. DOI: 10.1007/BF00166236. View

10.

Shankar L, Hoffman J, Bacharach S, Graham M, Karp J, Lammertsma A . Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006; 47(6):1059-66. View

11.

Zasadny K, Tatsumi M, Wahl R . FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003; 30(2):274-80. DOI: 10.1007/s00259-002-1022-z. View

12.

Van Den Abbeele A, Ertuk M . FDG-PET to Measure Response to Targeted Therapy: The Example of Gastrointestinal Stromal Tumor and Imatinib Mesylate (Gleevec). PET Clin. 2016; 3(1):77-87. DOI: 10.1016/j.cpet.2008.08.001. View

13.

Kunkel M, Forster G, Reichert T, Kutzner J, Benz P, Bartenstein P . Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol. 2003; 39(2):170-7. DOI: 10.1016/s1368-8375(02)00087-8. View

14.

Nitin N, Carlson A, Muldoon T, El-Naggar A, Gillenwater A, Richards-Kortum R . Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. Int J Cancer. 2009; 124(11):2634-42. PMC: 2700039. DOI: 10.1002/ijc.24222. View

15.

Dunn T, Braun R, Rhemus W, Rosner G, Secomb T, Tozer G . The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer. 1999; 80(1-2):117-26. PMC: 2363007. DOI: 10.1038/sj.bjc.6690330. View

16.

Mankoff D, Dunnwald L, Gralow J, Ellis G, Charlop A, Lawton T . Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002; 43(4):500-9. View

17.

Mankoff D, Dunnwald L, Gralow J, Ellis G, Schubert E, Tseng J . Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003; 44(11):1806-14. View

18.

Yamada K, Saito M, Matsuoka H, Inagaki N . A real-time method of imaging glucose uptake in single, living mammalian cells. Nat Protoc. 2007; 2(3):753-62. DOI: 10.1038/nprot.2007.76. View

19.

Zhong J, Rajaram N, Brizel D, Frees A, Ramanujam N, Batinic-Haberle I . Radiation induces aerobic glycolysis through reactive oxygen species. Radiother Oncol. 2013; 106(3):390-6. PMC: 3770265. DOI: 10.1016/j.radonc.2013.02.013. View

20.

Kallinowski F, Schlenger K, Kloes M, Stohrer M, Vaupel P . Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer. 1989; 44(2):266-72. DOI: 10.1002/ijc.2910440214. View